NEW YORK--(BUSINESS WIRE)--
Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in three upcoming investment conferences.
Juan José Chacón-Quirós, Chief Executive Officer and Founder, and Raj Denhoy, Chief Financial Officer, will participate in the 2024 UBS Global Healthcare Conference being held November 11-14, 2024. Mr. Chacón-Quirós and Mr. Denhoy are scheduled to speak to conference attendees on Tuesday, November 12 at 2:00-2:35 PM PST.
Mr. Chacón-Quirós will participate in the 2024 Jefferies London Healthcare Conference held November 19-21, 2024. Mr. Chacón-Quirós is scheduled to speak in person to conference attendees on Wednesday, November 20 at 7:30-7:55 AM GMT.
Mr. Denhoy will participate in the 2024 Stephens Annual Investment Conference, being held on November 19-21, 2024. Mr. Denhoy is scheduled to speak in person to conference attendees on Thursday, November 21 at 12:00-12:45 PM CST.
Live webcasts of the presentations will be available to all interested parties on the Establishment Labs investor relations website at . Archived versions of the webcasts will be available on the same website following the completion of the events.
About Establishment Labs
Establishment Labs Holdings Inc. is a global medical technology company dedicated to improving women’s health and wellness through the power of science, engineering, and technology. The Company offers a portfolio of Femtech solutions for breast health, breast aesthetics and breast reconstruction. The nearly four million Motiva® devices Establishment Labs has delivered to plastic and reconstructive surgeons since 2010 have created a new standard for safety and patient satisfaction in the over 85 countries in which they are available. The Motiva Flora® tissue expander is used to improve outcomes in breast reconstruction following breast cancer and it is the only regulatory-approved expander in the world with an integrated port using radio-frequency technology that is MRI conditional. Mia Femtech™, Establishment Lab’s unique minimally invasive experience for breast harmony, is the Company’s most recent breakthrough innovation. These solutions are supported by over 200 patent applications in 20 separate patent families worldwide and over 100 scientific and clinical studies and publications in peer reviewed journals. Establishment Labs manufactures at two facilities in Costa Rica compliant with all applicable regulatory standards under ISO13485:2016 and FDA 21 CFR 820 under the MDSAP program. Please visit our website for additional information at .
View source version on businesswire.com:
